1,5,7,8-TETRAHYDRO-2-METHYL-4H-THIOPYRANO[4,3-D]PYRIMIDIN-4-ONE
- ₹9277.03
- Product name: 1,5,7,8-TETRAHYDRO-2-METHYL-4H-THIOPYRANO[4,3-D]PYRIMIDIN-4-ONE
- CAS: 284028-90-6
- MF: C8H10N2OS
- MW: 182.24
- EINECS:200-589-5
- MDL Number:MFCD08703132
- Synonyms:1,5,7,8-TETRAHYDRO-2-METHYL-4H-THIOPYRANO[4,3-D]PYRIMIDIN-4-ONE;DR 2313;7,8-Dihydro-2-methyl-1H-thiopyrano[4,3-d]pyrimidin-4(5H)-one;3,5,7,8-Tetrahydro-2-methyl-4H-thiopyrano[4,3-d]pyrimidin-4-one;4H-Thiopyrano[4,3-d]pyriMidin-4-one,3,5,7,8-tetrahydro-2;4H-THIOPYRANO[4,3-D]PYRIMIDIN-4-ONE,3,5,7,8-TETRAHYDRO-2-METHYL-;SC-202756;2-Methyl-1-sulfanyl-1H,4H,5H,7H,8H-pyrano[4,3-d]pyriMidin-4-one
1 prices
Selected condition:
Brand
- Sigma-Aldrich(India)
Package
- 5MG
- ManufacturerSigma-Aldrich(India)
- Product numberSML0397
- Product descriptionDR2313 ≥98% (HPLC)
- Packaging5MG
- Price₹9277.03
- Updated2022-06-14
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Sigma-Aldrich(India) | SML0397 | DR2313 ≥98% (HPLC) | 5MG | ₹9277.03 | 2022-06-14 | Buy |
Properties
Boiling point :349.3±52.0 °C(Predicted)
Density :1.46±0.1 g/cm3(Predicted)
storage temp. :Sealed in dry,2-8°C
solubility :H2O: >2mg/mL (warmed)
pka :1.54±0.20(Predicted)
form :powder
color :white to beige
Density :1.46±0.1 g/cm3(Predicted)
storage temp. :Sealed in dry,2-8°C
solubility :H2O: >2mg/mL (warmed)
pka :1.54±0.20(Predicted)
form :powder
color :white to beige
Safety Information
Symbol(GHS): | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|
Description
PARP Inhibitor XI, DR2313 is a water soluble pyrimidinone compound that functions as a PARP (Poly(ADP-ribose) polymerase) inhibitor. PARP (Poly(ADP-ribose) polymerase) function by triggering DNA repair mechanisms and activating apoptosis in damaged cells. Studies show that DR2313 competes with NAD+ but does not display selectivity among PARP-1 and PARP-2. In addition, in vitro studies of cerebral ischemia exhibiting an overactivation of PARP show that ischemic damage can be reduced by introducing DR2313.Related product price
- NU1025
₹20250-24583.58 - 3-Aminobenzamide
₹4000-74180 - 4-AMINO-1,8-NAPHTHALIMIDE
₹9180-27521